ISMPP Highlights
Global Transparency & Trends Committee Conducts ISMPP Member Survey
In 2017, The MAP newsletter introduced the membership to the ISMPP Global Transparency & Trends Committee (GTTC), which aims to keep members updated on recent developments and current best practices for data and financial transparency. One of the Committee remits was to better understand…
Medical Writer Joint Position Statement Recognized Worldwide
Over the past several months, the Joint Position Statement on the Role of Professional Medical Writers (JPS) has received various organizational endorsements, has had related journal articles published about it, and has been translated into new languages…
ISMPP West – A Perfect Niche for Smaller Biotech and Pharma
The first-ever ISMPP West meeting was filled with excitement and engagement for attendees from smaller biotech and pharmaceutical companies, as well as larger companies. The meeting program addressed a niche for those who work in publication teams – or are a team of one…
Message from Our Leadership
Chris Winchester
Chair, 2018-2019 ISMPP Board of Trustees
News and Trends
Understanding Culture and Practices with Medical Publications Delivery in Japan
ISMPP membership in Japan has been growing in recent years, underlining the increasing importance of publications planning and execution in a country with potentially unique education needs regarding available treatments to better patients’ lives. Japan has…
The Year in Review/The Year Ahead
“The Year in Review/The Year Ahead” is designed to spotlight notable topics in 2018 and assess potential impact for the coming year. The topics were suggested by The MAP Working Group, then matched with subject matter experts. Commentary and perspective clarify each topic, offer insight into the practical implications…
A Renewed Focus on Author Disclosures in Biomedical Journals
On September 8, 2018, the New York Times, in collaboration with ProPublica, a nonprofit investigative journalism group, reported that a leading oncologist at Memorial Sloan Kettering Cancer Center (MSKCC) in New York had failed to report financial relationships with multiple pharmaceutical companies…